Pharmaceuticals behemoth Pfizer Inc (NYSE:PFE) shares remained resilient after broker Jefferies trimmed its price target on the pharmaceutical giant's stock to $42 from $40, as Pfizer leadership prepares to decide whether to separate its global established business from the rest of the company.
The break-up plan comes after a scuppered merger with Allergan PLC (NYSE:AGN) in April.
Pfizer shares closed Monday up 0.8% at $34.50.